Haemonetics
298 hedge funds and large institutions have $4.05B invested in Haemonetics in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 126 increasing their positions, 103 reducing their positions, and 48 closing their positions.
283% more call options, than puts
Call options by funds: $22.3M | Put options by funds: $5.82M
22% more repeat investments, than reductions
Existing positions increased: 126 | Existing positions reduced: 103
18% more capital invested
Capital invested by funds: $3.44B → $4.05B (+$603M)
0.05% more ownership
Funds ownership: 107.88% → 107.93% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less funds holding
Funds holding: 314 → 298 (-16)
29% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$50.4M |
| 2 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$31.8M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$30M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$18.3M |
| 5 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$39.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$31.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$29M |
| 4 |
Squarepoint
New York
|
-$14.7M |
| 5 |
Citigroup
New York
|
-$12.6M |
HAE Hedge Fund Activity: Q2 2025 in Review
298 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2025, worth a combined $4.05B — up 18% from $3.44B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of HAE and 34 opened new positions — a net loss of 14 holders — while 103 trimmed existing stakes and 126 added.
The largest buyer was Victory Capital Management, adding an estimated $50.4M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $39.8M.
- 298 institutional investors held Haemonetics (HAE) as of Q2 2025, down from 314 in Q1 2025.
- Funds reported $4.05B of Haemonetics stock for Q2 2025, up 18% quarter-over-quarter.
- 34 funds opened new Haemonetics positions in Q2 2025 and 48 closed out, a net change of -14 holders.
- The largest Haemonetics buyer in Q2 2025 was Victory Capital Management, an estimated $50.4M added.
- The largest Haemonetics seller in Q2 2025 was T. Rowe Price Investment Management, an estimated $39.8M sold.
Based on aggregated 13F filings for Q2 2025.